Yana Dekempeneer

Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

A. Windhorst, N. Devoogdt, Q. Lecocq, 2020, Cancers.

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.

P. Albertsson, V. Caveliers, T. Lahoutte, 2019, Molecular pharmaceutics.

Antibody for the Treatment of HER2 Cancer

V. Caveliers, T. Lahoutte, F. Bruchertseifer, 2022 .

The Therapeutic Potential of Anti-HER2 2Rs15d Nanobody Labeled with 225Ac – an In Vitro and In Vivo Evaluation

T. Lahoutte, F. Bruchertseifer, A. Morgenstern, 2019, Journal of Medical Imaging and Radiation Sciences.

Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

N. Devoogdt, Q. Lecocq, C. Goyvaerts, 2023, The Journal of Nuclear Medicine.

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Marleen Keyaerts, Nick Devoogdt, Tony Lahoutte, 2016, Expert opinion on biological therapy.

The therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of ovarian cancer.

B. Miller, Q. Lecocq, V. Caveliers, 2020, Molecular pharmaceutics.

Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer

B. Miller, M. Wojewódzka, V. Caveliers, 2022, Molecular Cancer Therapeutics.